On August 19, 2026, Korro Bio announced the submission of an application to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121. This GalNAc-conjugated RNA editing oligonucleotide is in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders (UCDs). The trial aims to determine safety, tolerability, pharmacokinetics, and efficacy in healthy volunteers and participants with UCDs under ClinicalTrials.gov identifier NCT 07773246. Korro Bio operates as a biopharmaceutical company focused on developing genetic medicines.

Korro Bio reported a net loss of $18.9 million for the quarter ended June 30, 2026, compared to $25.8 million in the prior year period. The company ended the quarter with $137.9 million in cash and marketable securities, providing a runway into the second half of 2028. Korro received Orphan Drug Designation from the European Medicines Agency for KRRO-121 to treat urea cycle disorders and nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, with preclinical data showing over 90% editing of pathogenic transcripts. Additionally, Korro entered into an exchange agreement with VenRock Healthcare Capital Partners on August 5, 2026, whereby VenRock surrendered 1,000,000 shares for no consideration in exchange for pre-funded warrants to purchase 1,000,000 shares at $0.001 per share exercise price with no expiration date. Following the transaction, Korro had 13,725,646 common shares outstanding and unexercised pre-funded warrants for an additional 4,148,836 shares. Korro Bio is a biopharmaceutical company developing genetic medicines using its proprietary RNA editing platform.